Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.8182.

DNLI has been the topic of several research reports. The Goldman Sachs Group upped their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus boosted their target price on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. BTIG Research upped their price target on Denali Therapeutics from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd.

Denali Therapeutics Stock Performance

DNLI opened at $20.65 on Friday. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $23.77. The stock has a market capitalization of $3.27 billion, a PE ratio of -6.95 and a beta of 1.10. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $20.49 and a two-hundred day moving average price of $18.05.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter last year, the business earned ($0.67) EPS. As a group, equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of institutional investors have recently bought and sold shares of DNLI. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares during the last quarter. Baillie Gifford & Co. increased its holdings in Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after buying an additional 1,615,565 shares during the period. Temasek Holdings Private Ltd lifted its stake in Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares during the period. Finally, State Street Corp boosted its holdings in Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after buying an additional 799,110 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.